Table 1.

Clinicopathologic and demographic characteristics of bladder cancer group (n = 210) among investigated patterns of RARβ2,APC methylation, and cytology

Clinicopathologic factors (n = 210)Methylation of urinary RARβ2 promoterMethylation of urinary APC promoterPositive urine cytology (n = 91)
Unmethylated(n = 193)Methylated (n = 130)Unmethylated (n = 196)Methylated (n = 125)
Age
 ≤52 years (n = 62)57 (92%)30 (48.4%)52 (83.3%)41 (66.7%)31 (50%)
 >52 years (n = 148)136 (91.8%)100 (67.6%)144 (97.3%)84 (56.8%)60 (40.5%)
Gender
 Male (n = 145)136 (93.8%)90 (62.1%)136 (93.5%)86 (59.6%)67 (46.2%)
 Female (n = 65)57 (87.7%)40 (61.5%)60 (92.3%)39 (60%)24 (36.9%)
Bilharziasis
 −ve (n = 82)79 (96.3%)49 (59.8%)82 (100%)55 (67.7%)23 (28%)
 +ve (n = 128)114 (89%)81 (63.3%)114 (89%)70 (54.7%)68 (53.1%) χ2 = 4.4, P = 0.036
Smoking
 −ve (n = 90)88 (97.5%)65 (72.2%)85 (94.4%)40 (44.4%)25 (27.8%)
 +ve (n = 120)105 (87.5%)65 (54.2%)111 (92.5%)85 (70.8%)66 (55%) χ2 = 6.65, P = 0.01
Pathologic type
 SCC (n = 53)50 (94.3%)33 (62.3%)53 (100%)39 (73.6%)14 (26.4%)
 TCC (n = 112)102 (91.1%)75 (66.9%)104 (93.6%)63 (56.3%)52 (46.4%)
Adenocarcinoma (n = 45)41 (91.1%)22 (48.9%)39 (86.7%)23 (51.1%)25 (55.6%)
Histologic grades
 1 (n = 43)39 (90.7%)36 (83.7%)38 (88.4%)24 (55.8%)14 (32.6%)
 2 (n = 110)101 (91.8%)64 (58.2%)104 (94.5%)65 (59.1%)51 (46.4%)
 3 (n = 57)53 (92.9%)30 (52.6%)54 (94.7%)36 (63.2%)26 (45.6%)
Clinical stages
 I (n = 77)74 (96.1%)54 (70%)70 (90.9%)45 (58.4%)41 (53.2%)
 II (n = 67)62 (92.5%)35 (52.2%)63 (94%)43 (64.2%)29 (43.3%)
 III (n = 30)23 (76.6%)16 (53.3%)30 (100%)22 (73.3%)7 (23.3%)
 IV (n = 36)34 (94.4%)25 (69.4%)33 (91.7%)15 (41.7%)14 (38.9%)